The 15th JFCR−ISCC
December 2-3, 2010
Hotel Nikko Tokyo, Tokyo
The 15th JFCR-International Symposium on Cancer Chemotherapy (ISCC) is scheduled on December 2 (Thu) and 3 (Fri), 2010, at the Hotel Nikko Tokyo, Daiba, Tokyo, Japan. I sincerely like to ask you to participate in the Symposium.
The Symposium (JFCR-ISCC) aims at exchanging and discussing the latest information on cancer chemotherapy focusing on clinical development of new anti-cancer drugs and future perspectives at the global level. Application trials of genomic technologies and bioinformatics become a major trend in clinical development of new anti-cancer drugs today. However, their impacts on this field are still dependent on cases and need to be experienced with more drugs and occasions. Updating information on favored and also un-favored cases in world-wide clinical trials would be essential for improvement of our own status. In coming 15th Symposium, new developing strategies of tyrosine kinase inhibitors, TGFβ signal inhibitors in relation to cancer stem cells, drug-conjugated antibody and developing better combination therapy are scheduled to be discussed as major topics. I believe this occasion would be an excellent opportunity for you to access the domestic and international information on clinical trials of cancer chemotherapy.
Many international co-operative studies are in fact ongoing for developing new anti-cancer drugs and such world-wide, harmonized study should become much more important in the future. I hope the Symposium will both encourage international cooperation in cancer chemotherapy and stimulate basic and clinical investigators in Japan.
Looking forward to seeing you in the Symposium,
Mitsuaki Yoshida, PhD Chairman, JFCR-ISCC Director, Cancer Chemotherapy Center Japanese Foundation for Cancer Research (JFCR) |
(*Program update)
December 2, 2010 (Thursday)
12:00-12:30
(Committee Meeting)
Opening Remark
13:00-13:10
Mitsuaki Yoshida (Cancer Chemotherapy Center, Tokyo)
I Nuclear Targets
Chairpersons: Jean-Pierre Armand (Institut Claudius Regaud, Toulouse)
Saburo Sone (Tokushima University, Tokushima)
13:10-13:45
Jaap Verweij (Erasmus University Medical Center, Rotterdam)
Clinical progress with PARP inhibition
13:45-14:20
Yves G. Pommier (National Cancer Institute, Bethesda)
Novel topoisomerases inhibitors in early clinical trials
14:20-14:30
Discussion
14:30-14:50
Coffee Break
II PI3 kinase inhibitors
Chairpersons: Barbara Klencke (Genentech, South San Francisco)
Michihiko Kuwano (Kyushu University, Fukuoka)
14:50-15:25
Takao Yamori (Cancer Chemotherapy Center, Tokyo)
Characterization of a new PI3 kinase inhibitor ZSTK474
15:25-16:00
Josep Tabernero (Vall d'Hebron University Hospital, Barcelona)
PI3K inhibitors, BEZ235 and BKM120
16:00-16:10
Discussion
III New drugs and new targets
Chairpersons: Tomoki Naoe (Nagoya University, Nagoya)
Yoshimasa Uehara (Iwate Medical University, Morioka)
16:10-16:45
Masuo Yamaoka (Takeda Pharmaceutical Co. Ltd., Tsukuba)
Antiandrogens for prostate cancer therapy
16:45-17:20
Karl-Heinz Altmann (Eidgenössische Technische Hochschule Zürich, Zürich)
Epothilones as lead structures for anticancer drug discovery
17:20-17:50
*Barbara Klencke (Genentech, South San Francisco)
Trastuzumab-DM1(T-DM1) antibody-drug conjugate (ADC): Bridging targeted therapy and conventional chemotherapy
17:50-18:00
Discussion
18:10-19:40
Mixer
December 3, 2010 (Friday)
IV Tyrosine kinase inhibitors
Chairpersons: Jaap Verweij (Erasmus University Medical Center, Rotterdam)
Yoshikazu Sugimoto (Keio University, Tokyo)
09:00-09:35
Shinya Kimura (Saga University, Saga)
Abl tyrosine kinase inhibitors
09:35-10:10
Hiroyuki Mano (Jichi Medical University, Tochigi/University of Tokyo, Tokyo)
Targeting ALK-fusion kinases
10:10-10:45
Mark Ratain (University of Chicago, Chicago)
Brivanib, a combined VEGFR and FGFR inhibitor
10:45-10:55
Discussion
10:55-11:15
Coffee Break
Special Lecture I
Chairperson: Tetsuichiro Muto (Cancer Institute Hospital, Tokyo)
11:15-11:55
Bruce A. Chabner (MGH Cancer Center, Boston)
Finding optimal combinations of molecular targeted agents
Luncheon Seminar I
Sponsored by University of Tokyo, Pharmaceutical Sciences Alumni
Chairperson: Toshihiko Kobayashi (University of Tokyo)
12:10-13:10
Karl-Heinz Altmann (Eidgenössische Technische Hochschule Zürich)
Kinase inhibitors as anticancer drugs: potential and limitation
Luncheon Seminar II
Sponsored by Novartis Pharma KK and EFPIA
Chairperson: Ken Kobayashi (Novartis Pharma KK)
12:10-13:10
Josep Tabernero (Vall d'Hebron University Hospital, Barcelona)
An overview of the different approaches to inhibit the PI3K pathway
Special Lecture II
Chairperson: Yves G. Pommier (National Cancer Institute, Bethesda)
13:30-14:10
Kohei Miyazono (University of Tokyo, Tokyo)
TGF-β signaling for the maintenance of glioma-initiating cells
V Cancer stem cells and TGF-beta signaling
Chairpersons:
Mark Ratain (University of Chicago, Chicago)
Yoshiro Niitsu (Sapporo Medical University, Sapporo)
14:10-14:45
Atsushi Hirao (Kanazawa University, Kanazawa)
Molecular mechanisms regulating maintenance of leukemia stem cells
14:45-15:15
Karl-Hermann Schlingensiepen (Antisense Pharma, Regensburg)
Targeted tumor treatment with Trabedersen (AP12009)
15:15-15:25
Discussion
15:25-15:45
Coffee Break
VI New modes for drug development
Chairpersons: Bruce A. Chabner (MGH Cancer Center, Boston)
Takao Yamori (Cancer Chemotherapy Center, Tokyo)
15:45-16:15
*Jennifer Low (Genentech, South San Francisco)
Hedgehog pathway inhibitor GDC-0449 in oncology
16:15-16:50
Jean-Pierre Armand (Institut Claudius Regaud, Toulouse)
Phase 0 clinical trial oncology/Microdosing
16:50-17:00
Discussion
Closing Remark
17:00-17:10
Bruce A Chabner (MGH Cancer Center, Boston)
For further information
please contact:
Masako Sasaki
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Ariake 3-8-31, Koto-ku, Tokyo 135-8550, Japan
TEL: 81-3-3520-0111 (ex. 5413) FAX: 81-3-3570-0482
